275 reports of this reaction
1.8% of all ROMOSOZUMAB AQQG reports
#11 most reported adverse reaction
SPINAL FRACTURE is the #11 most commonly reported adverse reaction for ROMOSOZUMAB AQQG, manufactured by Amgen, Inc. There are 275 FDA adverse event reports linking ROMOSOZUMAB AQQG to SPINAL FRACTURE. This represents approximately 1.8% of all 15,195 adverse event reports for this drug.
Patients taking ROMOSOZUMAB AQQG who experience spinal fracture should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SPINAL FRACTURE is a less commonly reported adverse event for ROMOSOZUMAB AQQG, but still significant enough to appear in the safety profile.
In addition to spinal fracture, the following adverse reactions have been reported for ROMOSOZUMAB AQQG:
SPINAL FRACTURE has been reported as an adverse event in 275 FDA reports for ROMOSOZUMAB AQQG. This does not prove causation, but indicates an association observed in post-market surveillance data.
SPINAL FRACTURE accounts for approximately 1.8% of all adverse event reports for ROMOSOZUMAB AQQG, making it a notable side effect.
If you experience spinal fracture while taking ROMOSOZUMAB AQQG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.